Macrophage Activation Syndrome clinical trials at UCLA
2 research studies open to eligible people
PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE
open to eligible people ages 6 months to 80 years
The purpose of this study is to assess the safety, tolerability and efficacy of emapalumab in children and adults with macrophage activation syndrome (sHLH/MAS) in Still's disease (including systemic juvenile idiopathic arthritis and adult onset Still's disease) or with sHLH/MAS in systemic lupus erythematous, resenting an inadequate response to high dose glucocorticoid treatment.
Los Angeles, California and other locations
Macrophage Activation syndromE in STill's Disease
open to eligible people ages 6 months to 80 years
Assessment of Macrophage activation syndrome in STill's disease: retrospective chart analysis of patient History, Symptom resolution and Treatment characteristics
Los Angeles, California and other locations
Last updated: